Combination Chemotherapy in Advanced Small Bowel Adenocarcinoma

Vol. 69, No. 4, 2005

Free Abstract Article (Fulltext) Article (PDF 102 KB)

Clinical Study

Combination Chemotherapy in Advanced Small Bowel Adenocarcinoma
Christophe Locher^a, David Malka^a, Valérie Boige^a, Pascal Lebray^a, Dominique Elias^b, Philippe Lasser^b, Michel Ducreux^a

^aGastroenterology Unit and
^bDepartment of Surgery, Institut Gustave Roussy, Villejuif, France

Address of Corresponding Author

Oncology 2005;69:290-294 (DOI: 10.1159/000089678)

Key Words

Small bowel adenocarcinoma
Chemotherapy
5-Fluorouracil
Platinum compounds
Irinotecan

Abstract

Objective: To assess the efficacy of 5-fluorouracil (5-FU) and either platinum compounds or irinotecan in patients with advanced small bowel adenocarcinoma (SBA), for whom data on the efficacy of chemotherapy are scarce. Methods: We reviewed data on all patients with advanced SBA who received chemotherapy over a 9-year period at our institution. Results: Twenty patients with advanced SBA received a median of 6 cycles (range 2-15) of chemotherapy with 5-FU and either cisplatin (n = 15), carboplatin (n = 2), or oxaliplatin (n = 3). The overall response rate was 21%, and median progression-free and overall survival 8 and 14 months, respectively. Toxicity was moderate. Second-line chemotherapy with 5-FU and irinotecan resulted in disease stabilization in 4 (50%) of 8 patients (median progression-free survival: 5 months), and in a biological complete response in another patient with nonmeasurable peritoneal carcinomatosis, allowing surgical cytoreduction surgery and hyperthermic intraperitoneal chemotherapy. No tumor response or disease stabilization was seen among the patients who received protracted venous infusion of 5-FU (n = 4) or infusional 5-FU and cisplatin (n = 1) as second-line chemotherapy. Conclusion: Chemotherapy with 5-FU and platinum compounds seems effective and well-tolerated in patients with advanced SBA. 5-FU-irinotecan combination chemotherapy deserves further investigation in the first-line setting.

Author Contacts

Dr. David Malka
Unité de Gastro-Entérologie, Institut Gustave Roussy
39 rue Camille-Desmoulins
FR-94805 Villejuif Cedex (France)
Tel. +33 1 42 11 43 28, Fax +33 1 42 11 52 29, E-Mail malka@igr.fr

Article Information

Received: December 3, 2004
Accepted after revision: May 25, 2005
Published online: November 9, 2005
Number of Print Pages : 5
Number of Figures : 2, Number of Tables : 1, Number of References : 21

Medline Abstract (ID 16282708)

Download Citation

Cited In

For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.